 |
Ability Pharmaceuticals |
ABTL1014 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Leukaemia and Lymphomas |
2RP |
|
ABTL1014
Therapeutic area:
Blood and Lymphatic systems
Cancer
|
|
Ability Pharmaceuticals |
ABTL0812 |
Biodrugs/ Drugs |
Cancer |
Lung, Endometrial and Pancreatic Cancer |
4PhII |
|
ABTL0812
Therapeutic area:
Cancer
|
|
Ability Pharmaceuticals |
ABTL0815 |
Biodrugs/ Drugs |
Cancer |
Solid Tumors |
1NRP |
|
ABTL0815
Therapeutic area:
Cancer
|
 |
Almirall |
P3074 |
Biodrugs/ Drugs |
Dermatology |
Androgenetic Alopecia |
5PhIII |
|
P3074
Therapeutic area:
Dermatology
|
|
Almirall |
PAT001 |
Biodrugs/ Drugs |
Dermatology
Genetic Diseases and Dysmorphic syndromes |
Ichthyosis |
4PhII |
|
PAT001
Therapeutic area:
Dermatology
Genetic Diseases and Dysmorphic syndromes
|
|
Almirall |
ADP13612 |
Biodrugs/ Drugs |
Dermatology |
Rosacea |
2RP |
|
ADP13612
Therapeutic area:
Dermatology
|
|
Almirall |
KX2-391 |
Biodrugs/ Drugs |
Dermatology |
Actinic keratosis |
5PhIII |
|
KX2-391
Therapeutic area:
Dermatology
|
|
Almirall |
ADP12734 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Dermatology |
Psoriasis |
2RP |
|
ADP12734
Therapeutic area:
Autoimmune & Inflammation
Dermatology
|
|
Almirall |
ADP12778 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Dermatology |
Atopic dermatitis |
2RP |
|
ADP12778
Therapeutic area:
Autoimmune & Inflammation
Dermatology
|
|
Almirall |
Tildrakizumab |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Dermatology |
Psoriasis |
6Reg. |
|
Tildrakizumab
Therapeutic area:
Autoimmune & Inflammation
Dermatology
|
|
Almirall |
P3058 |
Biodrugs/ Drugs |
Dermatology |
Onychomycosis |
5PhIII |
|
P3058
Therapeutic area:
Dermatology
|
 |
Aptatargets |
ApTOLL-01 |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Central Nervous System |
Acute ischemic stroke
Acute coronary syndrome |
2RP |
|
ApTOLL-01
Therapeutic area:
Cardiovascular and circulatory systems
Central Nervous System
|
|
Aptatargets |
ApTOLL-03 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Multiple Sclerosis |
1NRP |
|
ApTOLL-03
Therapeutic area:
Autoimmune & Inflammation
|
 |
APTUS Biotech |
ApTLR-4FT |
Biodrugs/ Drugs |
Central Nervous System |
Acute stroke |
1NRP |
|
ApTLR-4FT
Therapeutic area:
Central Nervous System
|
 |
Araclon Biotech |
ABvac40 |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's Disease |
4PhII |
|
ABvac40
Therapeutic area:
Central Nervous System
|
 |
Archivel Farma |
RUTI |
Vaccines |
Cancer |
Bladder cancer. |
3PhI |
|
RUTI
Therapeutic area:
Cancer
|
|
Archivel Farma |
RUTI® |
Vaccines |
Infections |
Active tuberculosis - Latent Tuberculosis |
4PhII |
Europe and South Africa |
RUTI®
Therapeutic area:
Infections
|
 |
ASCIL Biopharm |
ONYMED for nail diseases |
Biodrugs/ Drugs |
Dermatology |
ONYMED is an innovative long acting technology platform designed to provide a safer and more efficient way to treat or prevent nail disorders and diseases. ONYMED allows to dramatically reduce the dose and the frequency of treatment. For licensing. |
3PhI |
|
ONYMED for nail diseases
Therapeutic area:
Dermatology
|
|
ASCIL Biopharm |
APOC new treatment for NET |
Biodrugs/ Drugs |
Cancer |
APOC is a new drug product containing octreotide, the best in class somatostatin analogue (SSA) and the cornerstone of therapy for patients with Neuroendocrine Tumors (NETs) and acromegaly. ASCIL is selecting partner(s) for pivotal phase III studies. |
4PhII |
|
APOC new treatment for NET
Therapeutic area:
Cancer
|
 |
ATRYS HEALTH |
NILO1 |
Biodrugs/ Drugs |
Cancer
Central Nervous System |
Brain tumor and brain lesions |
1NRP |
Spain |
NILO1
Therapeutic area:
Cancer
Central Nervous System
|
 |
BIOFABRI |
MTBVAC |
Vaccines |
Infections
Respiratory and Pulmonary system |
Vaccine against Tuberculosis. MTBVAC is a live, attenuated vaccine, manufactured by Biofabri from a genetically modified strain from a human isolate. MTBVAC is in Phase 2A clinical trials in newborns and adults in South Africa. |
4PhII |
|
MTBVAC
Therapeutic area:
Infections
Respiratory and Pulmonary system
|
 |
Bioibérica |
Hialsorb intra-articular injection |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Indicated for treatment of degenerative or mechanical joint diseases |
6Reg. |
Spain |
Hialsorb intra-articular injection
Therapeutic area:
Musculoskeletal Disorders
|
|
Bioibérica |
BIS014 |
Biodrugs/ Drugs |
Analgesia & Pain
Central Nervous System |
Neuropathic pain |
2RP |
Europe |
BIS014
Therapeutic area:
Analgesia & Pain
Central Nervous System
|
|
Bioibérica |
Condrosan |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Symptomatic treatment of osteoarthritis |
6Reg. |
Spain |
Condrosan
Therapeutic area:
Musculoskeletal Disorders
|
|
Bioibérica |
Droglican |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Symptomatic treatment of knee osteoarthritis |
6Reg. |
Spain |
Droglican
Therapeutic area:
Musculoskeletal Disorders
|
|
Bioibérica |
Cartisorb |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Symptomatic treatment of osteoarthritis |
6Reg. |
Spain |
Cartisorb
Therapeutic area:
Musculoskeletal Disorders
|
|
Bioibérica |
Duartron |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Alleviation of mild to moderate osteoarthritis of the knee |
6Reg. |
|
Duartron
Therapeutic area:
Musculoskeletal Disorders
|
 |
Bioncotech Therapeutics |
BO-112 |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
3PhI |
|
BO-112
Therapeutic area:
Cancer
|
 |
Bionure |
BN201 |
Biodrugs/ Drugs |
Central Nervous System
Ophthalmology and optometry |
Acute Optic Neuritis, Neuromyelitis Optica, Multiple Sclerosis |
3PhI |
|
BN201
Therapeutic area:
Central Nervous System
Ophthalmology and optometry
|
 |
DIOMUNE SL |
IV1303 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Cardiovascular and circulatory systems
Genetic Diseases and Dysmorphic syndromes
Infections |
Sepsis treatment, Stroke, Rare diseases (CDH), Leishmania, ZIKV |
2RP |
|
IV1303
Therapeutic area:
Autoimmune & Inflammation
Cardiovascular and circulatory systems
Genetic Diseases and Dysmorphic syndromes
Infections
|
 |
ENTRECHEM |
EC-8042 iv for Ewing sarcoma |
Biodrugs/ Drugs |
Cancer |
Solid tumours |
2RP |
|
EC-8042 iv for Ewing sarcoma
Therapeutic area:
Cancer
|
|
ENTRECHEM |
EC-8042 iv for Triple negative breast cancer |
Biodrugs/ Drugs |
Cancer |
Triple negative breast cancer |
2RP |
|
EC-8042 iv for Triple negative breast cancer
Therapeutic area:
Cancer
|
|
ENTRECHEM |
Brasilicardin analogs |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Immunosupression |
1NRP |
|
Brasilicardin analogs
Therapeutic area:
Autoimmune & Inflammation
|
|
ENTRECHEM |
EC-8042 iv for liposarcoma |
Biodrugs/ Drugs |
Cancer |
liposarcoma myxoide |
2RP |
|
EC-8042 iv for liposarcoma
Therapeutic area:
Cancer
|
|
ENTRECHEM |
EC-70124 po for TNBC |
Biodrugs/ Drugs |
Cancer |
Triple negative breast cancer |
2RP |
|
EC-70124 po for TNBC
Therapeutic area:
Cancer
|
|
ENTRECHEM |
EC-70124 po for AML |
Biodrugs/ Drugs |
Cancer |
Acute myeloid leukemia |
2RP |
|
EC-70124 po for AML
Therapeutic area:
Cancer
|
|
ENTRECHEM |
EC-70124 po for prostate cancer |
Biodrugs/ Drugs |
Cancer |
Castration resistant prostate cancer |
2RP |
|
EC-70124 po for prostate cancer
Therapeutic area:
Cancer
|
 |
ESTEVE |
EGT-301 |
Gene / Cell Therapy |
Genetic Diseases and Dysmorphic syndromes |
Hunter syndrome: Lysosomal storage disease |
1NRP |
|
EGT-301
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
ESTEVE |
EGT-101 |
Gene / Cell Therapy |
Genetic Diseases and Dysmorphic syndromes |
Sanfilippo A syndrome:Lysosomal storage rare disease |
2RP |
|
EGT-101
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
ESTEVE |
EGT-201 |
Gene / Cell Therapy |
Genetic Diseases and Dysmorphic syndromes |
Sanfilippo B syndrome: Lisosomal storage rare disease |
1NRP |
|
EGT-201
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
ESTEVE |
MUMO1 |
Biodrugs/ Drugs |
Analgesia & Pain |
Acute and chronic, moderate to severe pain |
2RP |
|
MUMO1
Therapeutic area:
Analgesia & Pain
|
|
ESTEVE |
E-52862 |
Biodrugs/ Drugs |
Analgesia & Pain |
Neuropathic Pain |
4PhII |
|
E-52862
Therapeutic area:
Analgesia & Pain
|
|
ESTEVE |
E-58425 |
Biodrugs/ Drugs |
Analgesia & Pain |
Acute and chronic, moderate to severe pain |
5PhIII |
|
E-58425
Therapeutic area:
Analgesia & Pain
|
 |
FECYT |
Pylori |
Biodrugs/ Drugs |
Infections |
H. pylori |
2RP |
|
Pylori
Therapeutic area:
Infections
|
|
FECYT |
p300 |
Biodrugs/ Drugs |
Cancer |
Cancer |
2RP |
|
p300
Therapeutic area:
Cancer
|
|
FECYT |
p38 |
Biodrugs/ Drugs |
Analgesia & Pain
Central Nervous System |
Neuropathic Pain |
2RP |
|
p38
Therapeutic area:
Analgesia & Pain
Central Nervous System
|
 |
FERRER |
Lorediplon |
Biodrugs/ Drugs |
Central Nervous System |
Sleep disorders |
4PhII |
|
Lorediplon
Therapeutic area:
Central Nervous System
|
|
FERRER |
FAB-112 |
Gene / Cell Therapy |
Ophthalmology and optometry |
Corneal Diseases |
2RP |
|
FAB-112
Therapeutic area:
Ophthalmology and optometry
|
|
FERRER |
Ozenoxacin |
Biodrugs/ Drugs |
Dermatology
Infections |
Dermal infections |
6Reg. |
|
Ozenoxacin
Therapeutic area:
Dermatology
Infections
|
|
FERRER |
FAB-120 |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Diabetic Retinopathy |
2RP |
|
FAB-120
Therapeutic area:
Ophthalmology and optometry
|
|
FERRER |
FAB-117 |
Gene / Cell Therapy |
Central Nervous System |
Spinal Cord Injury |
3PhI |
|
FAB-117
Therapeutic area:
Central Nervous System
|
 |
FUND. PROGRESO Y SALUD |
FISEVI 141 |
Biodrugs/ Drugs |
Infections |
Sepsis, Acute lung injury |
2RP |
|
FISEVI 141
Therapeutic area:
Infections
|
|
FUND. PROGRESO Y SALUD |
FIBAO-13007 |
Gene / Cell Therapy |
Cancer |
Cancer cells |
2RP |
|
FIBAO-13007
Therapeutic area:
Cancer
|
|
FUND. PROGRESO Y SALUD |
Autologous Bone Marrow Mononuclear cells |
Gene / Cell Therapy |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Critical Limb Ischemia in diabetic patients |
3PhI |
|
Autologous Bone Marrow Mononuclear cells
Therapeutic area:
Cardiovascular and circulatory systems
Metabolic / Endocrinology
|
|
FUND. PROGRESO Y SALUD |
FISEVI-13002 |
Biodrugs/ Drugs |
Cancer |
Multiple myeloma |
2RP |
|
FISEVI-13002
Therapeutic area:
Cancer
|
|
FUND. PROGRESO Y SALUD |
FIMABIS-99 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Nanoemulsions for the treatment of obesity |
2RP |
|
FIMABIS-99
Therapeutic area:
Metabolic / Endocrinology
|
|
FUND. PROGRESO Y SALUD |
FIBAO-91 Melatonine Solution |
Biodrugs/ Drugs |
Infections |
Sepsis |
4PhII |
|
FIBAO-91 Melatonine Solution
Therapeutic area:
Infections
|
|
FUND. PROGRESO Y SALUD |
FISEVI-121 |
Gene / Cell Therapy |
Autoimmune & Inflammation |
Transplant |
2RP |
|
FISEVI-121
Therapeutic area:
Autoimmune & Inflammation
|
|
FUND. PROGRESO Y SALUD |
FIMABIS-77 |
Biodrugs/ Drugs |
Central Nervous System |
Hydroxytyrosol ethers |
2RP |
|
FIMABIS-77
Therapeutic area:
Central Nervous System
|
|
FUND. PROGRESO Y SALUD |
Allogeneic Adipose Mesenchymal stem cells / Allodepleted Bone Marrow Progenitors |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Blood and Lymphatic systems |
Chronic Graft versus Host Disease, Haematological Malignancies |
4PhII |
|
Allogeneic Adipose Mesenchymal stem cells / Allodepleted Bone Marrow Progenitors
Therapeutic area:
Autoimmune & Inflammation
Blood and Lymphatic systems
|
|
FUND. PROGRESO Y SALUD |
Engineered Corneas |
Gene / Cell Therapy |
Ophthalmology and optometry |
Corneal ulcers |
4PhII |
|
Engineered Corneas
Therapeutic area:
Ophthalmology and optometry
|
|
FUND. PROGRESO Y SALUD |
CABIMER-14001 Condon plasma factors for skin regeneration |
Gene / Cell Therapy |
Autoimmune & Inflammation
Dermatology |
Dermatitis |
1NRP |
|
CABIMER-14001 Condon plasma factors for skin regeneration
Therapeutic area:
Autoimmune & Inflammation
Dermatology
|
|
FUND. PROGRESO Y SALUD |
Autologous Bone Marrow progenitors, Adipose and Bone Marrow Mesenchymal stem cells |
Gene / Cell Therapy |
Autoimmune & Inflammation
Central Nervous System |
Stroke, Multiple Sclerosis and ALS |
4PhII |
|
Autologous Bone Marrow progenitors, Adipose and Bone Marrow Mesenchymal stem cells
Therapeutic area:
Autoimmune & Inflammation
Central Nervous System
|
|
FUND. PROGRESO Y SALUD |
FIMABIS-13001 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Treatment and/or Prevention of Non-alcoholic fatty liver disease (NAFLD) |
2RP |
|
FIMABIS-13001
Therapeutic area:
Metabolic / Endocrinology
|
|
FUND. PROGRESO Y SALUD |
CABIMER-11 New target gene and delivery systems for the Treatment of Retinitis Pigmentosa |
Gene / Cell Therapy |
Ophthalmology and optometry |
Retinitis pigmentosa |
1NRP |
|
CABIMER-11 New target gene and delivery systems for the Treatment of Retinitis Pigmentosa
Therapeutic area:
Ophthalmology and optometry
|
|
FUND. PROGRESO Y SALUD |
Autologous Bone Marrow Mononuclear cells and Adipose Mesenchymal stem cells |
Gene / Cell Therapy |
Digestive System |
Extended Liver resection, Faecal Incontinence |
4PhII |
|
Autologous Bone Marrow Mononuclear cells and Adipose Mesenchymal stem cells
Therapeutic area:
Digestive System
|
|
FUND. PROGRESO Y SALUD |
FIMABIS-13007 |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Treatment and/or prevention of metabolic and cardiovascular diseases |
2RP |
|
FIMABIS-13007
Therapeutic area:
Cardiovascular and circulatory systems
Metabolic / Endocrinology
|
|
FUND. PROGRESO Y SALUD |
CABIMER-13003 |
Vaccines |
Central Nervous System |
Parkinson |
1NRP |
|
CABIMER-13003
Therapeutic area:
Central Nervous System
|
|
FUND. PROGRESO Y SALUD |
Autologous Bone Marrow Mononuclear cells |
Gene / Cell Therapy |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Acute Myocardial Infarction/Dilated Myocardiopathy/Chronic Ischemic Cardiopathy/Critical Limb Ischemia in diabetic & non patients |
4PhII |
|
Autologous Bone Marrow Mononuclear cells
Therapeutic area:
Cardiovascular and circulatory systems
Metabolic / Endocrinology
|
|
FUND. PROGRESO Y SALUD |
FISEVI-14012 |
Biodrugs/ Drugs |
Infections |
Multirresistant infections |
2RP |
|
FISEVI-14012
Therapeutic area:
Infections
|
|
FUND. PROGRESO Y SALUD |
FIBICO-14003 |
Gene / Cell Therapy |
Musculoskeletal Disorders |
Musculoskeletal disorders |
1NRP |
|
FIBICO-14003
Therapeutic area:
Musculoskeletal Disorders
|
|
FUND. PROGRESO Y SALUD |
FIMABIS-14003 |
Biodrugs/ Drugs |
Dermatology
Infections |
Treatment of mucocutaneous herpes infections |
4PhII |
|
FIMABIS-14003
Therapeutic area:
Dermatology
Infections
|
|
FUND. PROGRESO Y SALUD |
FISEVI-13007 |
Gene / Cell Therapy |
Cancer |
Hepatocarcinoma |
2RP |
|
FISEVI-13007
Therapeutic area:
Cancer
|
|
FUND. PROGRESO Y SALUD |
FIBICO-14002 |
Biodrugs/ Drugs |
Cancer |
Metastatic processes and resistant cancers |
1NRP |
|
FIBICO-14002
Therapeutic area:
Cancer
|
|
FUND. PROGRESO Y SALUD |
FRM-5 |
Gene / Cell Therapy |
Others |
Transplant |
2RP |
|
FRM-5
Therapeutic area:
Others
|
|
FUND. PROGRESO Y SALUD |
FIBAO-13014 Combination of Ketamine and Meperidine |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Mucositis |
3PhI |
|
FIBAO-13014 Combination of Ketamine and Meperidine
Therapeutic area:
Autoimmune & Inflammation
|
|
FUND. PROGRESO Y SALUD |
FISEVI-13020 |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
2RP |
|
FISEVI-13020
Therapeutic area:
Central Nervous System
|
|
FUND. PROGRESO Y SALUD |
FIBAO-116 |
Biodrugs/ Drugs |
Analgesia & Pain |
Fibromyalgia |
3PhI |
|
FIBAO-116
Therapeutic area:
Analgesia & Pain
|
 |
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) |
Advanced cell therapies |
Gene / Cell Therapy |
Ophthalmology and optometry |
Eye rare diseases |
4PhII |
Spain / Europe |
Advanced cell therapies
Therapeutic area:
Ophthalmology and optometry
|
|
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) |
Mutli-target siRNA approach |
Gene / Cell Therapy |
Autoimmune & Inflammation
Kidney and Genitourinary system |
Chronic Kidney Disease (CKD)/ Akute Kidney Injury (AKI) |
2RP |
|
Mutli-target siRNA approach
Therapeutic area:
Autoimmune & Inflammation
Kidney and Genitourinary system
|
|
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) |
New generation of peptides |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Blood and Lymphatic systems
Cardiovascular and circulatory systems
Kidney and Genitourinary system
Metabolic / Endocrinology
Ophthalmology and optometry |
Chronic complications of Diabetes / Choric kidney disease |
2RP |
|
New generation of peptides
Therapeutic area:
Autoimmune & Inflammation
Blood and Lymphatic systems
Cardiovascular and circulatory systems
Kidney and Genitourinary system
Metabolic / Endocrinology
Ophthalmology and optometry
|
|
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) |
Peptide derived from a natural compound |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Metabolic / Endocrinology |
Osteoporosis treatment |
1NRP |
|
Peptide derived from a natural compound
Therapeutic area:
Autoimmune & Inflammation
Metabolic / Endocrinology
|
|
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) |
Advanced cell therapies |
Gene / Cell Therapy |
Blood and Lymphatic systems
Cancer |
Oncology / Haematological disorders |
3PhI |
Spain / US |
Advanced cell therapies
Therapeutic area:
Blood and Lymphatic systems
Cancer
|
 |
Fundacion MEDINA |
MDN-005 |
Biodrugs/ Drugs |
Central Nervous System
Musculoskeletal Disorders |
Amyotrophic lateral sclerosis (ALS) |
1NRP |
|
MDN-005
Therapeutic area:
Central Nervous System
Musculoskeletal Disorders
|
|
Fundacion MEDINA |
MDN-0147; MDN-0148 & MDN-0149 |
Biodrugs/ Drugs |
Cancer |
Melanoma |
1NRP |
|
MDN-0147; MDN-0148 & MDN-0149
Therapeutic area:
Cancer
|
|
Fundacion MEDINA |
MDN-088 |
Biodrugs/ Drugs |
Cancer |
Breast, Colon & Lung Cancer |
1NRP |
|
MDN-088
Therapeutic area:
Cancer
|
|
Fundacion MEDINA |
MDN-0145; MDN-0146 |
Biodrugs/ Drugs |
Central Nervous System |
Parkinson |
1NRP |
|
MDN-0145; MDN-0146
Therapeutic area:
Central Nervous System
|
|
Fundacion MEDINA |
MDN-018 |
Biodrugs/ Drugs |
Infections |
Fungal Infections |
1NRP |
|
MDN-018
Therapeutic area:
Infections
|
|
Fundacion MEDINA |
MDN-057/MDN-058/MDN-059 |
Biodrugs/ Drugs |
Infections |
Gram negative infections |
1NRP |
|
MDN-057/MDN-058/MDN-059
Therapeutic area:
Infections
|
|
Fundacion MEDINA |
MDN-0090 |
Biodrugs/ Drugs |
Cancer |
Pancreatic Cancer |
1NRP |
|
MDN-0090
Therapeutic area:
Cancer
|
|
Fundacion MEDINA |
MDN-0109, MDN-110, MDN-111, MDN- 112 |
Biodrugs/ Drugs |
Infections |
Malaria |
1NRP |
|
MDN-0109, MDN-110, MDN-111, MDN- 112
Therapeutic area:
Infections
|
 |
Genmedica Therapeutics |
GMC-252 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Type 2 Diabetes |
3PhI |
Europe |
GMC-252
Therapeutic area:
Metabolic / Endocrinology
|
 |
GP-PHARM |
Lutrate Depot 22,5 mg |
Biodrugs/ Drugs |
Cancer |
Prostate Cancer |
6Reg. |
|
Lutrate Depot 22,5 mg
Therapeutic area:
Cancer
|
|
GP-PHARM |
Desmopresina Solution |
Biodrugs/ Drugs |
Kidney and Genitourinary system |
Nocturnal Enuresis |
6Reg. |
|
Desmopresina Solution
Therapeutic area:
Kidney and Genitourinary system
|
|
GP-PHARM |
Triptorelina Depot 1-3 |
Biodrugs/ Drugs |
Cancer |
Prostate Cancer |
3PhI |
|
Triptorelina Depot 1-3
Therapeutic area:
Cancer
|
|
GP-PHARM |
Lutrate Depot 45 mg |
Biodrugs/ Drugs |
Cancer |
Prostate Cancer |
3PhI |
Worldwide |
Lutrate Depot 45 mg
Therapeutic area:
Cancer
|
|
GP-PHARM |
Pegylated Liposomes for Oncology |
Biodrugs/ Drugs |
Cancer |
Advanced Ovarian Cancer, Advanced Breast Cancer |
3PhI |
Worldwide |
Pegylated Liposomes for Oncology
Therapeutic area:
Cancer
|
|
GP-PHARM |
TERIPERATIDE |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Osteoporosis |
3PhI |
|
TERIPERATIDE
Therapeutic area:
Musculoskeletal Disorders
|
|
GP-PHARM |
depot form. |
Biodrugs/ Drugs |
Cancer |
Several |
3PhI |
|
depot form.
Therapeutic area:
Cancer
|
|
GP-PHARM |
Octeotride LAR |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Acromegaly |
4PhII |
Worldwide |
Octeotride LAR
Therapeutic area:
Metabolic / Endocrinology
|
 |
Histocell |
HR016 |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Acute Lung Injury |
2RP |
|
HR016
Therapeutic area:
Respiratory and Pulmonary system
|
|
Histocell |
HC016 |
Biodrugs/ Drugs |
Central Nervous System |
Acute Spinal Cord Injury |
4PhII |
|
HC016
Therapeutic area:
Central Nervous System
|
|
Histocell |
HR004 |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Bone Regeneration |
4PhII |
|
HR004
Therapeutic area:
Musculoskeletal Disorders
|
 |
IIS La Fe |
Mutant of candida albicans and use in therapy against candidiasis |
Biodrugs/ Drugs |
Infections |
Mutant of candida albicans and use in therapy against candidiasis |
1NRP |
|
Mutant of candida albicans and use in therapy against candidiasis
Therapeutic area:
Infections
|
 |
InKemia IUCT group |
DIS-COM-BRA |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Asthma |
1NRP |
|
DIS-COM-BRA
Therapeutic area:
Respiratory and Pulmonary system
|
|
InKemia IUCT group |
IUCT-DS-0263 |
Biodrugs/ Drugs |
Cancer |
Prostate cancer |
1NRP |
Europe |
IUCT-DS-0263
Therapeutic area:
Cancer
|
|
InKemia IUCT group |
DIS-COM-BRA |
Biodrugs/ Drugs |
Analgesia & Pain
Autoimmune & Inflammation |
Inflammation |
1NRP |
|
DIS-COM-BRA
Therapeutic area:
Analgesia & Pain
Autoimmune & Inflammation
|
|
InKemia IUCT group |
IUCT-DS-0423 |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
1NRP |
|
IUCT-DS-0423
Therapeutic area:
Cancer
|
|
InKemia IUCT group |
IUCT-DS-0347 |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
1NRP |
|
IUCT-DS-0347
Therapeutic area:
Cancer
|
|
InKemia IUCT group |
IUCT-DS-0263 |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
1NRP |
|
IUCT-DS-0263
Therapeutic area:
Cancer
|
|
InKemia IUCT group |
IUCT-DS-0086 |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
1NRP |
|
IUCT-DS-0086
Therapeutic area:
Cancer
|
|
InKemia IUCT group |
DIS-COM-COAG |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Anticoagulants |
1NRP |
|
DIS-COM-COAG
Therapeutic area:
Cardiovascular and circulatory systems
|
|
InKemia IUCT group |
DIS-BIO-EPS |
Biodrugs/ Drugs |
Analgesia & Pain
Autoimmune & Inflammation |
Osteoarthritis |
1NRP |
|
DIS-BIO-EPS
Therapeutic area:
Analgesia & Pain
Autoimmune & Inflammation
|
|
InKemia IUCT group |
DIS-BIO-VIR |
Biodrugs/ Drugs |
Infections |
Antivirals |
1NRP |
|
DIS-BIO-VIR
Therapeutic area:
Infections
|
|
InKemia IUCT group |
DIS-BIO-CAN |
Biodrugs/ Drugs |
Cancer |
Antineoplastic |
1NRP |
|
DIS-BIO-CAN
Therapeutic area:
Cancer
|
|
InKemia IUCT group |
IUCT-DS-0423 |
Biodrugs/ Drugs |
Cancer |
Prostate cancer |
1NRP |
|
IUCT-DS-0423
Therapeutic area:
Cancer
|
|
InKemia IUCT group |
DIS-COM-TROP |
Biodrugs/ Drugs |
Central Nervous System |
Migraine |
1NRP |
|
DIS-COM-TROP
Therapeutic area:
Central Nervous System
|
|
InKemia IUCT group |
IUCT-DS-0347 |
Biodrugs/ Drugs |
Cancer |
Prostate cancer |
1NRP |
Europe |
IUCT-DS-0347
Therapeutic area:
Cancer
|
 |
Institut Quimic de Sarrià (IQS) |
Chondro-implant |
Gene / Cell Therapy |
Cardiovascular and circulatory systems |
Bioactive implant for myocardial regeneration, ventricular support and elliptical shape restoration. Acute Cartilage Injure |
1NRP |
|
Chondro-implant
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Institut Quimic de Sarrià (IQS) |
Cardio-implant |
Gene / Cell Therapy |
Cardiovascular and circulatory systems |
PCL (Polycaprolactone), SAP (self-assembling peptide) bioactive and biomimetic scaffolds for cartilage regeneration. Heart infarct |
1NRP |
|
Cardio-implant
Therapeutic area:
Cardiovascular and circulatory systems
|
 |
Iproteos |
IPR-166 |
Biodrugs/ Drugs |
Central Nervous System |
Cognitive Impairment Associated with Schizophrenia (CIAS) |
2RP |
|
IPR-166
Therapeutic area:
Central Nervous System
|
|
Iproteos |
IPR-179 |
Biodrugs/ Drugs |
Central Nervous System |
Epilepsy |
1NRP |
|
IPR-179
Therapeutic area:
Central Nervous System
|
 |
IRYCIS |
New compound for the treatment of isquemical stroke |
Biodrugs/ Drugs |
Central Nervous System |
Isquemic stroke |
1NRP |
Spain |
New compound for the treatment of isquemical stroke
Therapeutic area:
Central Nervous System
|
 |
Leukos Biotech |
LK-01 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
AML |
3PhI |
|
LK-01
Therapeutic area:
Blood and Lymphatic systems
Cancer
|
 |
Lipopharma Therapeutics |
LP30171 |
Biodrugs/ Drugs |
Cancer
Metabolic / Endocrinology |
Metabolic Diseases, cancer |
1NRP |
|
LP30171
Therapeutic area:
Cancer
Metabolic / Endocrinology
|
|
Lipopharma Therapeutics |
LP205A1 |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Central Nervous System
Metabolic / Endocrinology |
Cardiovascular and Metabolic Diseases, CNS, |
1NRP |
|
LP205A1
Therapeutic area:
Cardiovascular and circulatory systems
Central Nervous System
Metabolic / Endocrinology
|
|
Lipopharma Therapeutics |
LPA181 |
Biodrugs/ Drugs |
Central Nervous System |
Spinal Cord Injury, Pain. Global rigths outlicensed to a third party biotech company |
2RP |
|
LPA181
Therapeutic area:
Central Nervous System
|
|
Lipopharma Therapeutics |
LP226A1 |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's Disease |
2RP |
|
LP226A1
Therapeutic area:
Central Nervous System
|
|
Lipopharma Therapeutics |
LP204A1 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Cardiovascular and circulatory systems |
Inflammation, Cardiovascular |
1NRP |
|
LP204A1
Therapeutic area:
Autoimmune & Inflammation
Cardiovascular and circulatory systems
|
|
Lipopharma Therapeutics |
LP561A1 |
Biodrugs/ Drugs |
Cancer |
Glioma and other solid tumours |
4PhII |
|
LP561A1
Therapeutic area:
Cancer
|
 |
Minoryx |
MIN-102 |
Biodrugs/ Drugs |
Central Nervous System
Metabolic / Endocrinology |
X-linked Adrenoleukodystrophy |
4PhII |
|
MIN-102
Therapeutic area:
Central Nervous System
Metabolic / Endocrinology
|
 |
NATAC |
Retriacyl |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Retinitis Pigmentosa |
5PhIII |
Europe |
Retriacyl
Therapeutic area:
Ophthalmology and optometry
|
 |
Neurofix |
NFX91 |
Biodrugs/ Drugs |
Others |
Sleep disorders |
1NRP |
|
NFX91
Therapeutic area:
Others
|
|
Neurofix |
NFX88 |
Biodrugs/ Drugs |
Analgesia & Pain
Central Nervous System |
Neuropathic pain |
4PhII |
Spain |
NFX88
Therapeutic area:
Analgesia & Pain
Central Nervous System
|
|
Neurofix |
NFX81 |
Biodrugs/ Drugs |
Central Nervous System |
Spinal Cord Injuries |
2RP |
Spain |
NFX81
Therapeutic area:
Central Nervous System
|
 |
nLife Therapeutics, S.L. |
NLF-PD-1233 |
Biodrugs/ Drugs |
Central Nervous System |
Parkinson Disease |
2RP |
Europe and USA |
NLF-PD-1233
Therapeutic area:
Central Nervous System
|
 |
Oryzon |
ORY-3001 |
Biodrugs/ Drugs |
Others |
Non-oncological disease |
2RP |
|
ORY-3001
Therapeutic area:
Others
|
|
Oryzon |
OG-new series in KDM |
Biodrugs/ Drugs |
Cancer
Others |
Solid cancers, Oncohaematology |
1NRP |
|
OG-new series in KDM
Therapeutic area:
Cancer
Others
|
|
Oryzon |
ORY-2001 |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease, Multiple Sclerosis, Huntington's disease, other dementias, |
4PhII |
|
ORY-2001
Therapeutic area:
Central Nervous System
|
|
Oryzon |
ORY-1001 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Acute Myeloid Leukaemia, SCLC, other solid tumors; other oncohaematology indications |
4PhII |
|
ORY-1001
Therapeutic area:
Blood and Lymphatic systems
Cancer
|
 |
PaloBiofarma |
PBF-509 |
Biodrugs/ Drugs |
Cancer
Central Nervous System |
Lung Cancer |
4PhII |
Spain |
PBF-509
Therapeutic area:
Cancer
Central Nervous System
|
|
PaloBiofarma |
PBF680 |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Asthma |
4PhII |
Spain |
PBF680
Therapeutic area:
Respiratory and Pulmonary system
|
|
PaloBiofarma |
PBF-677 |
Biodrugs/ Drugs |
Digestive System |
Colitis |
4PhII |
Spain |
PBF-677
Therapeutic area:
Digestive System
|
|
PaloBiofarma |
PBF-1129 |
Biodrugs/ Drugs |
Cancer |
Lung Cancer |
3PhI |
Spain |
PBF-1129
Therapeutic area:
Cancer
|
|
PaloBiofarma |
PBF-999 |
Biodrugs/ Drugs |
Cancer |
Solid Tumors |
3PhI |
Spain |
PBF-999
Therapeutic area:
Cancer
|
 |
PharmaMar |
LURBINECTEDIN (PM1183) |
Biodrugs/ Drugs |
Cancer |
Ewing Sarcoma |
4PhII |
EU & NA |
LURBINECTEDIN (PM1183)
Therapeutic area:
Cancer
|
|
PharmaMar |
LURBINECTEDIN (PM1183) |
Biodrugs/ Drugs |
Cancer |
BRCA2 Pancreatic |
4PhII |
NA |
LURBINECTEDIN (PM1183)
Therapeutic area:
Cancer
|
|
PharmaMar |
LURBINECTEDIN (PM1183) |
Biodrugs/ Drugs |
Cancer |
Small Cell Lung Cancer |
4PhII |
EU & NA |
LURBINECTEDIN (PM1183)
Therapeutic area:
Cancer
|
|
PharmaMar |
LURBINECTEDIN (PM1183) |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
4PhII |
EU & NA |
LURBINECTEDIN (PM1183)
Therapeutic area:
Cancer
|
|
PharmaMar |
PM184 |
Biodrugs/ Drugs |
Cancer |
Colorectal Cancer |
4PhII |
EU & NA |
PM184
Therapeutic area:
Cancer
|
|
PharmaMar |
LURBINECTEDIN (PM1183) |
Biodrugs/ Drugs |
Cancer |
Endometrial cancer |
4PhII |
EU & NA |
LURBINECTEDIN (PM1183)
Therapeutic area:
Cancer
|
|
PharmaMar |
PM184 |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
3PhI |
EU & NA |
PM184
Therapeutic area:
Cancer
|
|
PharmaMar |
PM184 + TRABECTEDIN |
Biodrugs/ Drugs |
Cancer |
Soft tissue Sarcoma |
3PhI |
EU |
PM184 + TRABECTEDIN
Therapeutic area:
Cancer
|
|
PharmaMar |
PM14 |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
3PhI |
EU |
PM14
Therapeutic area:
Cancer
|
|
PharmaMar |
TRABECTEDIN + PLD |
Biodrugs/ Drugs |
Cancer |
Ovarian cancer (Japan) |
3PhI |
Japan |
TRABECTEDIN + PLD
Therapeutic area:
Cancer
|
|
PharmaMar |
LURBINECTEDIN (PM1183) |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
3PhI |
Japan |
LURBINECTEDIN (PM1183)
Therapeutic area:
Cancer
|
|
PharmaMar |
TRABECTEDIN + PLD |
Biodrugs/ Drugs |
Cancer |
Ovarian Cancer. |
5PhIII |
Europe |
TRABECTEDIN + PLD
Therapeutic area:
Cancer
|
|
PharmaMar |
TRABECTEDIN + Radiotherapy |
Biodrugs/ Drugs |
Cancer |
Sarcoma |
4PhII |
Europe |
TRABECTEDIN + Radiotherapy
Therapeutic area:
Cancer
|
|
PharmaMar |
TRABECTEDIN |
Biodrugs/ Drugs |
Cancer |
Retroperitoneal L-Sarcoma |
4PhII |
Italy |
TRABECTEDIN
Therapeutic area:
Cancer
|
|
PharmaMar |
LURBINECTEDIN (PM1183) |
Biodrugs/ Drugs |
Cancer |
Platinum-Resistant ovarian cancer. |
5PhIII |
Europe and NA |
LURBINECTEDIN (PM1183)
Therapeutic area:
Cancer
|
|
PharmaMar |
LURBINECTEDIN (PM1183) + DOXORUBICIN |
Biodrugs/ Drugs |
Cancer |
Small Cell lung cancer |
5PhIII |
EU , LA & LATAM |
LURBINECTEDIN (PM1183) + DOXORUBICIN
Therapeutic area:
Cancer
|
 |
PRAXIS |
NANOENZHIMES |
Biodrugs/ Drugs |
Genetic Diseases and Dysmorphic syndromes |
SANFILIPPO/FABRY |
1NRP |
|
NANOENZHIMES
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
PRAXIS |
Nanoantibiotics |
Gene / Cell Therapy |
Respiratory and Pulmonary system |
Resistent Infections (Cystic Fibrosis) |
1NRP |
|
Nanoantibiotics
Therapeutic area:
Respiratory and Pulmonary system
|
|
PRAXIS |
PROHEAL |
Biodrugs/ Drugs |
Dermatology |
Bioactive wound dressings (Diabetic / vascular) |
1NRP |
|
PROHEAL
Therapeutic area:
Dermatology
|
|
PRAXIS |
CLINGLIO |
Biodrugs/ Drugs |
Cancer |
Glioma |
4PhII |
|
CLINGLIO
Therapeutic area:
Cancer
|
|
PRAXIS |
ANTIAGE |
Biodrugs/ Drugs |
Dermatology |
ANTIAGING DRUGS AND NUTRACEUTICS |
1NRP |
|
ANTIAGE
Therapeutic area:
Dermatology
|
|
PRAXIS |
EPIPROT |
Biodrugs/ Drugs |
Dermatology |
Diabetic Foot |
5PhIII |
|
EPIPROT
Therapeutic area:
Dermatology
|
|
PRAXIS |
TAT-CF |
Biodrugs/ Drugs |
Genetic Diseases and Dysmorphic syndromes |
CYSTIC FIBROSIS |
1NRP |
|
TAT-CF
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
PRAXIS |
ATEROLESS |
Biodrugs/ Drugs |
Dermatology |
ANTIAGING COSMETIC AND NUTRACEUTICS |
1NRP |
|
ATEROLESS
Therapeutic area:
Dermatology
|
|
PRAXIS |
IGRALZHEIMER |
Biodrugs/ Drugs |
Central Nervous System |
ALZHEIMER |
1NRP |
|
IGRALZHEIMER
Therapeutic area:
Central Nervous System
|
|
PRAXIS |
TERARMET |
Biodrugs/ Drugs |
Others |
SANFILIPPO |
1NRP |
|
TERARMET
Therapeutic area:
Others
|
|
PRAXIS |
NANOPLATFORMM |
Biodrugs/ Drugs |
Infections |
NANOFORMULATION OF DRUGS FOR RESISTANT INFECTIONS |
1NRP |
|
NANOPLATFORMM
Therapeutic area:
Infections
|
|
PRAXIS |
NNE |
Biodrugs/ Drugs |
Dermatology |
Diabetic Foot |
1NRP |
|
NNE
Therapeutic area:
Dermatology
|
|
PRAXIS |
TERFIQEC |
Gene / Cell Therapy |
Genetic Diseases and Dysmorphic syndromes |
Cystic Fibrosis |
2RP |
|
TERFIQEC
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
PRAXIS |
BERENICE |
Biodrugs/ Drugs |
Genetic Diseases and Dysmorphic syndromes |
Chagas |
5PhIII |
|
BERENICE
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
PRAXIS |
NANOCANTHER |
Biodrugs/ Drugs |
Cancer |
THERAPY SYSTEMS FOR PANCREATIC CANCER |
1NRP |
|
NANOCANTHER
Therapeutic area:
Cancer
|
 |
REIG JOFRE |
Topical solution |
Biodrugs/ Drugs |
Dermatology |
Skin infections |
5PhIII |
Spain, Mexico |
Topical solution
Therapeutic area:
Dermatology
|
 |
Sanifit |
SNF472 |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Cardiovascular disease (dialysis) |
4PhII |
|
SNF472
Therapeutic area:
Cardiovascular and circulatory systems
Metabolic / Endocrinology
|
|
Sanifit |
SNF472 |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Calciphylaxis (dialysis) |
4PhII |
|
SNF472
Therapeutic area:
Cardiovascular and circulatory systems
Metabolic / Endocrinology
|
 |
SOM Biotech |
SOM3355 |
Biodrugs/ Drugs |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes |
Huntington's disease, Tourette syndrome and Tardive Dyskinesia |
4PhII |
|
SOM3355
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
|
|
SOM Biotech |
SOM1202 |
Biodrugs/ Drugs |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes |
Adrenomyeloneuropathy |
1NRP |
|
SOM1202
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
|
|
SOM Biotech |
SOM1201 |
Biodrugs/ Drugs |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes |
Adrenoleukodystrophy |
4PhII |
|
SOM1201
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
|
|
SOM Biotech |
SOM2201 |
Biodrugs/ Drugs |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Musculoskeletal Disorders |
Duchenne Muscular Dystrophy |
1NRP |
|
SOM2201
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Musculoskeletal Disorders
|
 |
SPHERIUM BIOMED |
SP13004 |
Biodrugs/ Drugs |
Cancer
Dermatology
Digestive System |
Prevention and treatment of radiochemotherapy-induced mucositis in head and neck cancer |
4PhII |
|
SP13004
Therapeutic area:
Cancer
Dermatology
Digestive System
|
|
SPHERIUM BIOMED |
SP12006 |
Biodrugs/ Drugs |
Analgesia & Pain
Musculoskeletal Disorders |
Treatment of mild to moderate muscular pain (related to sportive practice DOMS and Temporomandibular Joint Disorder) |
4PhII |
|
SP12006
Therapeutic area:
Analgesia & Pain
Musculoskeletal Disorders
|
|
SPHERIUM BIOMED |
SP14019 |
Biodrugs/ Drugs |
Dermatology |
topical spray of cyclosporine to treat Atopic Dermatitis & Psoriasis |
4PhII |
|
SP14019
Therapeutic area:
Dermatology
|
|
SPHERIUM BIOMED |
SP1440 |
Biodrugs/ Drugs |
Central Nervous System |
Small Mollecule. Schizophrenia and cognitive improvement |
2RP |
|
SP1440
Therapeutic area:
Central Nervous System
|
|
SPHERIUM BIOMED |
SP15016 |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Kidney and Genitourinary system |
Prevention of Acute Kidney Injury in Angioplasty patients receiving high dose contrast agent |
3PhI |
|
SP15016
Therapeutic area:
Cardiovascular and circulatory systems
Kidney and Genitourinary system
|
 |
Sylentis |
siRNA / SYL116011 |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Ocular Allergy |
2RP |
|
siRNA / SYL116011
Therapeutic area:
Ophthalmology and optometry
|
|
Sylentis |
siRNA / SYL1801 |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Retina |
2RP |
|
siRNA / SYL1801
Therapeutic area:
Ophthalmology and optometry
|
|
Sylentis |
Tivanisirán / SYL1001 |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Dry Eye Syndrome |
5PhIII |
|
Tivanisirán / SYL1001
Therapeutic area:
Ophthalmology and optometry
|
|
Sylentis |
Bamosiran / SYL040012 |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Ocular Hypertension, Glaucoma |
4PhII |
|
Bamosiran / SYL040012
Therapeutic area:
Ophthalmology and optometry
|
 |
TERACLON IDF |
V-32-R |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Glaucoma |
2RP |
|
V-32-R
Therapeutic area:
Ophthalmology and optometry
|
|
TERACLON IDF |
T1649 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Dermatology |
Psoriasis |
1NRP |
|
T1649
Therapeutic area:
Autoimmune & Inflammation
Dermatology
|
|
TERACLON IDF |
V32R |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Diabetic Retinopathy |
2RP |
|
V32R
Therapeutic area:
Ophthalmology and optometry
|
 |
Thrombotargets |
TT-112 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Antifibrinolysis |
1NRP |
|
TT-112
Therapeutic area:
Blood and Lymphatic systems
|
|
Thrombotargets |
TT-173 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Haemorrhage |
5PhIII |
|
TT-173
Therapeutic area:
Blood and Lymphatic systems
|
 |
VCN Biosciences |
VCN-01 |
Gene / Cell Therapy |
Cancer |
Retinoblastoma |
3PhI |
|
VCN-01
Therapeutic area:
Cancer
|
|
VCN Biosciences |
VCN-01 |
Gene / Cell Therapy |
Cancer |
Pancreatic cancer |
3PhI |
|
VCN-01
Therapeutic area:
Cancer
|
|
VCN Biosciences |
VCN-02 |
Gene / Cell Therapy |
Cancer |
Solid Tumors |
1NRP |
|
VCN-02
Therapeutic area:
Cancer
|
|
VCN Biosciences |
VCN-11 |
Gene / Cell Therapy |
Cancer |
Solid Tumors |
2RP |
|
VCN-11
Therapeutic area:
Cancer
|
|
VCN Biosciences |
VCN-01 |
Gene / Cell Therapy |
Cancer |
Head & Neck Cancer |
3PhI |
|
VCN-01
Therapeutic area:
Cancer
|
 |
VENTER PHARMA |
LacTEST 0,45 g |
Biodrugs/ Drugs |
Digestive System |
Evaluation of hypolactasia |
6Reg. |
|
LacTEST 0,45 g
Therapeutic area:
Digestive System
|
|
VENTER PHARMA |
LacTEST 2,7 g |
Biodrugs/ Drugs |
Digestive System |
Evaluation of hypolactasia |
5PhIII |
|
LacTEST 2,7 g
Therapeutic area:
Digestive System
|
 |
Vivia Biotech |
Vivia 009 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Central Nervous System |
Non Hodgkin Lymphoma, CNS |
2RP |
Europe |
Vivia 009
Therapeutic area:
Blood and Lymphatic systems
Central Nervous System
|
|
Vivia Biotech |
Vivia 011 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Obesity, Diabetes |
1NRP |
|
Vivia 011
Therapeutic area:
Metabolic / Endocrinology
|
 |
Vytrus Biotech |
PhyPsor |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Dermatology |
Psoriasis |
1NRP |
|
PhyPsor
Therapeutic area:
Autoimmune & Inflammation
Dermatology
|